摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,5-Dimethyl-2,3-dihydropyridazin-3-one | 337956-28-2

中文名称
——
中文别名
——
英文名称
2,5-Dimethyl-2,3-dihydropyridazin-3-one
英文别名
2,5-dimethylpyridazin-3-one
2,5-Dimethyl-2,3-dihydropyridazin-3-one化学式
CAS
337956-28-2
化学式
C6H8N2O
mdl
——
分子量
124.14
InChiKey
YYMGSACPTAPTGY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.2
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    32.7
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    参考文献:
    名称:
    TSUCHIYA T.; ARAI H.; HASEBE M.; IGETA H., CHEM. AND PHARM. BULL. , 1974, 22, NO 10, 2301-2305
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • NEW COMPOUNDS
    申请人:HAUEL Norbert
    公开号:US20100240669A1
    公开(公告)日:2010-09-23
    The present invention relates to the compounds of general formula I wherein n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and X are defined as described hereinafter, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the medicaments containing the pharmacologically effective compounds, the preparation thereof and the use thereof.
    本发明涉及一般式I的化合物,其中n、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11和X的定义如下所述,其对映体、非对映体、混合物及其盐,特别是其与有机或无机酸或碱形成的生理上可接受的盐,具有有价值的性质,其制备方法,含有药理学有效化合物的药物,其制备方法和用途。
  • 2-(CYCLIC AMINOCARBONYL)INDOLINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE SAME
    申请人:Dainippon Sumitomo Pharma Co., Ltd.
    公开号:EP1840126A1
    公开(公告)日:2007-10-03
    A compound of the following formula (I): wherein A is a group of the following formula (I-A): wherein X is an oxygen atom or a sulfur atom, R4 is a hydrogen atom, a C1-6 alkyl group, or other, R5 is a hydrogen atom or other; or a heteroaryl group or other optionally substituted with a halogen, a C1-6 alkyl, a C1-6 alkoxy, or other; R1 and R2 are the same or different and are a hydrogen atom, a C1-6 alkyl group or other; R3 is a hydrogen atom, a halogen atom, a C1-6 alkoxy group, or other; Ra and Rb are the same or different and are a hydrogen atom or a C1-6 alkyl group; and n is an integer of 0-5; or a pharmaceutically acceptable acid addition salt thereof, which can selectively act on mitochondrial benzodiazepine receptor and is useful as a medicament for treating/preventing anxiety disorder, depression, epilepsy, dementia, and so on.
    以下是公式(I)的化合物: 其中A是以下公式(I-A)的一个基团: 其中X是氧原子或原子,R4是氢原子,C1-6烷基或其他,R5是氢原子或其他;或者是杂环基团或其他,可选择地取代有卤素、C1-6烷基、C1-6烷氧基或其他;R1和R2相同或不同,是氢原子、C1-6烷基或其他;R3是氢原子、卤素原子、C1-6烷氧基或其他;Ra和Rb相同或不同,是氢原子或C1-6烷基;n是0-5的整数;或其药学上可接受的酸盐,可选择性地作用于线粒体苯二氮卓受体,用作治疗/预防焦虑症、抑郁症、癫痫、痴呆等疾病的药物。
  • 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same
    申请人:Kondo Katsunori
    公开号:US20080221114A1
    公开(公告)日:2008-09-11
    A compound of the following formula (I): wherein A is a group of the following formula (I-A): wherein X is an oxygen atom or a sulfur atom, R 4 is a hydrogen atom, a C 1-6 alkyl group, or other, R 5 is a hydrogen atom or other; or a heteroaryl group or other optionally substituted with a halogen, a C 1-6 alkyl, a C 1-6 alkoxy, or other; R 1 and R 2 are the same or different and are a hydrogen atom, a C 1-6 alkyl group or other; R 3 is a hydrogen atom, a halogen atom, a C 1-6 alkoxy group, or other; R a and R b are the same or different and are a hydrogen atom or a C 1-6 alkyl group; and n is an integer of 0-5; or a pharmaceutically acceptable acid addition salt thereof, which can selectively act on mitochondrial benzodiazepine receptor and is useful as a medicament for treating/preventing anxiety disorder, depression, epilepsy, dementia, and so on.
    以下化合物的化学式(I),其中A是以下化学式(I-A)的基团:其中X是氧原子或原子,R4是氢原子,C1-6烷基或其他,R5是氢原子或其他;或是杂环芳基或其他,可选择地用卤素,C1-6烷基,C1-6烷氧基或其他取代;R1和R2相同或不同,是氢原子,C1-6烷基或其他;R3是氢原子,卤素原子,C1-6烷氧基或其他;Ra和Rb相同或不同,是氢原子或C1-6烷基;n是0-5的整数;或其药学上可接受的酸加盐,可选择性地作用于线粒体苯二氮䓬受体,用作治疗/预防焦虑症、抑郁症、癫痫、痴呆症等药物。
  • HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS
    申请人:Nishino Taito
    公开号:US20120128640A1
    公开(公告)日:2012-05-24
    An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells containing a compound represented by the formula (I) (wherein X, Y, Z, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R6 and R 7 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof, which can expand hematopoietic stem cells and/or hematopoietic progenitor cells.
    提供一种用于改善基因治疗中将基因转移至造血干细胞以治疗各种疾病的血液干细胞和/或造血祖细胞扩张剂。该扩张剂包含由式(I)表示的化合物(其中X、Y、Z、Ar1、R1、R2、R3、R4、R5、R6和R7如描述中所定义)、该化合物的互变异构体、前药或药学上可接受的盐或其溶剂,能够扩张血液干细胞和/或造血祖细胞。
  • METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS
    申请人:Nissan Chemical Industries, Ltd.
    公开号:EP2765187A1
    公开(公告)日:2014-08-13
    An agent for inducing production of megakaryocytes and/or platelets from pluripotent stem cells which is useful for treatment of disease accompanied by a decrease in platelets is provided. A method for producing megakaryocytes and/or platelets, comprising separating hematopoietic progenitor cells from the septal cells in sac-like structures produced by pluripotent stem cells, and culturing the hematopoietic progenitor cells ex vivo in the presence of a compound represented by the formula (I) (wherein R1 to R7, W, X, Y, Z, Ar1 and n are as defined in the description) to differentiate them into megakaryocytes and/or platelets.
    提供了一种诱导多能干细胞产生巨核细胞和/或血小板的制剂,该制剂可用于治疗伴随血小板减少的疾病。 一种生产巨核细胞和/或血小板的方法,包括在多能干细胞产生的囊状结构中将造血祖细胞从隔细胞中分离出来,并在由式(I)代表的化合物(其中R1至R7、W、X、Y、Z、Ar1和n如描述中所定义)存在下体内外培养造血祖细胞,使其分化成巨核细胞和/或血小板。
查看更多